Autoimmune mucocutaneous blistering diseases (AMBDs) are rare but potentially life-threatening complications after hematopoietic SCT (HSCT). Linear IgA bullous dermatosis (LABD) is one type of AMBD, and clinically resembles bullous pemphigoid, dermatitis herpetiformis, cicatrical pemphigoid and pemphigus vulgaris. [1] [2] [3] It is histologically characterized by linear deposits of IgA at the basement membrane zone in immunofluorescent studies, and is usually provoked by infections, drugs or malignancies, especially lymphoproliferative disorders. 1, 3, 4 Here, we describe a patient with non-Hodgkin's lymphoma who developed LABD after autologous HSCT and was successfully treated with glucocorticoid, dapsone and high-dose i.v. Ig, but the lymphoma recurred in a short period of time.
A 54-year-old man was admitted to our hospital because of erythematous skin eruption with blistering formations. He had been diagnosed with Ann-Arbor stage III angioimmunoblastic T-cell lymphoma about 9 months ago and received six cycles of systemic chemotherapy (CY, doxorubicin, VCR, and prednisone). After systemic chemotherapy, he achieved CR and underwent an autologous PBSC transplantation with a conditioning protocol comprising BCNU (300 mg/m 2 on day À7), cytarabine (100 mg/m 2 twice daily from day À6 to day À3), etoposide (100 mg/m 2 twice daily from day À6 to day À3) and melphalan (140 mg/m 2 on day À2). He received a cell dose of CD34 5.42 Â 10 6 /kg and did not experience any severe post-transplant complications. He was engrafted on day 16. Prophylactic antimicrobials (levofloxacin, acyclovir and fluconazole) were discontinued after engraftment, and other medications were not used.
The patient first recognized bullous skin eruption on his abdomen and back on post-transplant day 72. This eruption extended to his face, buttocks, extremities and buccal mucosa over a 1-week period (Figure 1a ). An initial complete blood count showed a white cell count of 11 920/ mm 3 (51.0% neutrophils), hemoglobin level of 11.2 g/dl and platelet count of 51 000/mm 3 . On physical examination, there was no peripheral lymphadenopathy or hepatosplenomegaly. A biopsy of the skin was performed on a blister on the left thigh. The histological examination showed subepidermal blistering and a heavy neutrophilic infiltrate along the papillary dermis ( Figure 2a ). Direct immunofluorescence microscopy of the perilesional skin revealed continuous linear IgA deposition in the dermoepidermal junction ( Figure 2b ). However, no deposition of IgG, IgM or C3 was observed. With these results, the diagnosis of LABD was established, and therapy with methylprednisolone (2.0 mg/kg) and dapsone (100 mg once daily) was started immediately. Despite the use of this therapy, the bullous skin eruptions worsened after treatment for 1 week, and so we decided to add high-dose i.v. Ig (400 mg/kg for 5 days). After the addition of i.v. Ig, no new bullous lesions developed, and the lesions gradually resolved over 1 month. Methylprednisolone was tapered and changed to prednisolone, and dapsone was also tapered over 3 months. Although we could not completely eliminate the prednisolone and dapsone because of the waxing and waning of the bullous lesions, the patient's skin lesions markedly improved (Figure 1b) .
On post-transplant day 174, multiple lymph nodes were palpable in both the cervical and axillary regions. Excisional biopsy of the largest cervical lymph node revealed recurrent angioimmunoblastic T-cell lymphoma, and positron emission tomography and computed tomographic scanning obtained after the administration of 18 F-fluorodeoxyglucose revealed multiple hypermetabolic lymphadenopathies in the cervical, axillary, mediastinal and abdominal regions. Systemic chemotherapy with gemcitabine, dexamethasone and platinum was initiated, and the patient is presently undergoing salvage treatment. He will receive an allo-SCT from a matched unrelated donor if a CR or PR after salvage treatment is attained.
Most AMBDs following HSCT are associated with substantial morbidity and mortality. LABD following HSCT is an extremely rare disease, and only one case in which a patient with CML developed the disease after undergoing allogeneic HSCT has been reported. 2 Of note, this patient was well controlled by conventional treatment with topical glucocorticoid and systemic administration of dapsone. Contrary to this report, our patient was resistant to initial treatment with systemic glucocorticoid and dapsone. Recently, there has been evidence demonstrating the efficacy of i.v. Ig in patients with AMBDs that are resistant to conventional treatments, including glucocorticoids and other immunosuppressants.
3,5 I.v. Ig contains a polyclonal mixture of antibodies and, although its mechanism of action in patients with AMBDs is complex and not fully understood, i.v. Ig may produce its therapeutic effects through the following possible mechanisms: (1) by reducing the titers of circulating pathogenic autoantibodies through anti-idiotypic antibodies, (2) by saturating the Fc receptors of pathogenic autoantibodies, and (3) by inhibiting the pathogenic activation of T cells through antibodies to T-cell membrane molecules. 5 LABD is a type of AMBD and is characterized by circulating and tissue-bound IgA antibodies against heterogeneous antigens located in the cutaneous basement membrane zone. 3 Although randomized, controlled studies of i.v. Ig for treatment of LABD have not been performed, there are several reports supporting the use of i.v. Ig in patients with LABD, 6, 7 Given our experience and the previous reports, we feel that treatment with i.v. Ig in patients with LABD resistant to conventional treatment or having experienced complications as a result of conventional treatment has a reasonable chance of producing remission.
Interestingly, our patient experienced recurrence of his lymphoma within 100 days after the diagnosis of LABD. An association between LABD and lymphoproliferative malignancies has been reported. 4, 8 Moreover, paraneoplastic pemphigus, which is an AMBD related to an underlying neoplasia and is characterized by deposition of IgG and C3 at the basement membrane zone on direct immunofluorescence study, has been described as a distinct entity since it was first reported by Anhalt et al. 9 in 1990. In our patient, the temporal relationship between LABD and the recurrence of lymphoma raises the possibility of a paraneoplastic association. Further studies are needed to evaluate the possibility of LABD as a paraneoplastic manifestation, and clinicians should closely monitor for the recurrence of underlying malignancies in patients undergoing HSCT who developed LABD.
In conclusion, we presented a rare case of LABD following autologous HSCT in a patient with nonHodgkin's lymphoma. Performing an early skin biopsy in patients with mucocutaneous bullous lesions following HSCT is important because of the recent demonstration of the efficacy of i.v. Ig in treatment of LABD. It is also prudent to have a high index of suspicion for recurrence in patients with a history of malignancy who develop LABD.
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